Scientific article
Open access

Caution when using 1,3, β-D-glucan in the CSF as a biomarker of Candida albicans meningitis

Published inInternational journal of infectious diseases, vol. 122, p. 531-533
Publication date2022-09
First online date2022-06-26

Relying on a biomarker to diagnose or follow up the treatment of a Candida albicans meningitis would have an impact on patient management. The biomarker 1,3, β-D-glucan (BDG), developed for serum testing, shows inconsistent values when applied on cerebrospinal fluid (CSF), and its use with the current protocol on CSF samples warrants caution.

  • Biomarkers
  • Candida albicans
  • Humans
  • Meningitis
  • Proteoglycans
  • Beta-Glucans
Citation (ISO format)
BARBOLINI, Laura et al. Caution when using 1,3, β-D-glucan in the CSF as a biomarker of <i>Candida albicans</i> meningitis. In: International journal of infectious diseases, 2022, vol. 122, p. 531–533. doi: 10.1016/j.ijid.2022.06.033
Main files (1)
Article (Published version)
ISSN of the journal1201-9712

Technical informations

Creation01/05/2023 2:38:58 PM
First validation05/22/2023 3:43:30 PM
Update time05/22/2023 4:01:38 PM
Status update05/22/2023 4:01:38 PM
Last indexation08/31/2023 11:15:56 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack